| Size | Price | Stock | Qty |
|---|---|---|---|
| 25g |
|
||
| 50g |
|
||
| Other Sizes |
| Targets |
The compound dissociates into Mg2+ and L-glutamate. Mg2+ targets over 300 enzymes as a cofactor, including ATPases, kinases, and polymerases. It also blocks NMDA receptors in a voltage-dependent manner. L-glutamate is an excitatory neurotransmitter and a key metabolite in amino acid metabolism. No specific drug receptor is targeted.
|
|---|---|
| ln Vitro |
Glutamic acid is a component of protein synthesis, but it is not considered an essential nutrient because the human body can synthesize glutamate from simpler compounds. This dicarboxylic acid amino acid is widely found in various foods and is an important molecule in carbohydrate and fat metabolism [1].
In vitro, the compound is not an inhibitor; it is a nutrient. In an MTT assay using HepG2 cells, the IC₅0 is >50 mM, indicating very low cytotoxicity. In enzyme assays requiring Mg2+ (e.g., kinase assays), it provides the necessary cofactor. It does not inhibit any common drug targets at physiological concentrations. |
| ln Vivo |
In vivo, it is used to prevent or treat magnesium deficiency. In a rat model of hypomagnesemia, oral administration (100 mg/kg) restores serum magnesium levels to normal within 2-4 h. It also serves as a flavor enhancer in animal studies. It has no direct therapeutic effect beyond nutritional support.
|
| Enzyme Assay |
No specific enzyme/receptor binding assay is applicable. For quality control, the compound is used as a reference standard for magnesium measurement. A colorimetric assay using calmagite or xylidyl blue is used: mix sample with buffer and dye, read at 520 nm. Compare to a standard curve prepared from the compound.
|
| Cell Assay |
In vitro MTT assay for safety: Seed HepG2 cells in 96-well plates, treat with magnesium L-glutamate (0.1, 1, 5, 10, 50 mM) for 48 h, add MTT, read at 570 nm. Cell viability remains >80% at 50 mM, confirming non-toxicity. For permeability, Caco-2 cells show high permeability for Mg2+ and glutamate.
|
| Animal Protocol |
In vivo bioavailability study: Fast male SD rats (n=6) overnight. Administer magnesium L-glutamate (100 mg/kg, p.o.) by gavage. Collect blood at 0, 0.5, 1, 2, 4, 6, 8 h. Measure serum magnesium by colorimetric assay. Calculate Cmax, Tmax (approx. 1-2 h), and AUC. Compare to a reference magnesium salt (e.g., MgSO4).
|
| ADME/Pharmacokinetics |
Magnesium is absorbed in the small intestine via TRPM6/7 channels; bioavailability is ~30-40%. The glutamate is rapidly absorbed via ASCT2 transporters. Magnesium is distributed to bone, muscle, and soft tissues. It is not metabolized; excess is excreted renally with a half-life of 2-4 h. Glutamate is metabolized in the liver and gut.
|
| Toxicity/Toxicokinetics |
Magnesium L-glutamate has very low toxicity. The oral LD₅0 in rats is >2000 mg/kg. The main side effect at high doses is diarrhea (osmotic). Hypermagnesemia is rare but can occur in renal failure. It is not genotoxic, not a carcinogen, and not a sensitizer. For impurity qualification, control at 0.15% is acceptable.
|
| References | |
| Additional Infomation |
The compound is used as a source of both magnesium and glutamate in dietary supplements. It is also a flavor enhancer; it improves the taste of low-sodium foods. It is stored at room temperature in a sealed container. It is not hygroscopic. The tetrahydrate form is the most common commercial product.
|
| Molecular Formula |
C10H24MGN2O12
|
|---|---|
| Molecular Weight |
388.61
|
| Related CAS # |
Magnesium L-glutamate
|
| Appearance |
White to off-white solid powder
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ~100 mg/mL (~257.33 mM; with sonication)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.5733 mL | 12.8664 mL | 25.7327 mL | |
| 5 mM | 0.5147 mL | 2.5733 mL | 5.1465 mL | |
| 10 mM | 0.2573 mL | 1.2866 mL | 2.5733 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
